Should CD19 CAR-T Cells for ALL be Followed by Allogeneic Stem Cell Transplant?
Author:
Open Access
- 20 January 2022
- journal article
- editorial
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (1) , 1-2
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALLJournal of Clinical Oncology, 2021
- Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALLBlood, 2019
- Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trialAmerican Journal of Hematology, 2019
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsBlood, 2017
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsJournal of Clinical Investigation, 2016
- CAR-T Cell Therapy for LymphomaAnnual Review of Medicine, 2016
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow TransplantationBlood, 2010